Mary Eileen Dolan to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Mary Eileen Dolan has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.072
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.072